Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Clinical trial NCT05280470 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05280470
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-09
- Primary completion
- 2025-03-03
- Enrollment
- 187
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.